“This transaction delivers on our stated strategy to leverage our cardiac platform and operating model,” says Michael McKelvey, PhD, president and CEO of ERT. “This will support the remote collection, interpretation, and delivery of clinical efficacy and safety information critical for all phases of clinical research and provide support to leverage our core expertise into the larger healthcare market.”

The company paid $80.8 million in cash for CRS. Integrating CRS’s offerings into ERT’s portfolio provides several advantages, including the following:

?    Establishing ERT as a market leader in respiratory core lab services for clinical trials.
?    Providing diagnostic device capability.
?    Expanding revenue base in cardiac safety.
?    Significantly expanding ERT’s global footprint.

“We have tremendous respect for the entire CareFusion Research Services organization,” says McKelvey. “Both organizations share a strong commitment to client satisfaction, quality, scientific leadership, innovation, and dedication to employees.”